Nova Eye Medical Limited (ELXMF) Research

Headquartered in Kent Town, Australia, and established in 1985, Nova Eye Medical Limited is dedicated to the development, manufacturing, and global commercialization of surgical solutions for eye conditions, with a primary focus on glaucoma. Their product lineup features the iTrack surgical system, engineered to reduce intraocular pressure in adult patients with open-angle glaucoma, alongside its evolution, iTrack Advance, which promotes natural ocular fluid drainage. For individuals with severe or intricate forms of glaucoma, they provide the Molteno3 drainage device. Additionally, the company offers 2RT, a unique laser technology aimed at treating early to intermediate age-related macular degeneration. Nova Eye Medical Limited maintains a significant international footprint, conducting operations across Australia, the United States, Europe, and the Asia Pacific region. The company officially adopted its current name in July 2020, having previously operated as Ellex Medical Lasers Limited.

Market snapshot

Symbol
ELXMF
Price
$0.01
Day change
0.00%
Market cap
$31.3M
P/E ratio
-4.46x
52-week range
0.0019-0.1
Sector
Healthcare
Industry
Medical - Devices
Next earnings
in 2 months

Peer companies

  • Alternate Health Corp. (AHGIF)
  • Ecofibre Limited (EOFBF)
  • ImpediMed Limited (IPDQF)
  • Novacyt S.A. (NVYTF)
  • Next Science Limited (NXSCF)
  • PetVivo Holdings, Inc. (PETV)
  • Positron Corporation (POSC)
  • Provectus Biopharmaceuticals, Inc. (PVCT)

Open Nova Eye Medical Limited (ELXMF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.